Alzheimer’s patients in Biogen trial, jolted by revival of drug, press for access once again
When Biogen halted studies of its Alzheimer's drug, trial participants had been devastated. The revival of the drug on Tuesday was a jolt.
When Jeff Borghoff saw the article Tuesday morning, the first thing he did was double-check the date it was published. He thought it might be years old, not a breaking story.
In Pennsylvania, Phil Gutis saw a Facebook post about the announcement. “What the hell?” he wondered.
Before March, both had been enrolled in a clinical trial for an experimental Alzheimer’s therapy from the drug maker Biogen. When the studies were halted because the drug, aducanumab, did not appear to be working, they had been devastated.
On Tuesday, however, the company announced that a new data analysis showed the treatment reduced some patients’ decline; it said it would ask the
